Vascular disrupting agents

Journal of Cellular Biochemistry

Volumn 99, Issue 4, 2006, Pages 1021-1039

  Pilat, M J ^a   LoRusso, P M ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Tumor endothelium; Tumor vasculature; Vascular disruption; Vascular targeting

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ABT 751; ADENOSINE TRIPHOSPHATE; ADH 1; ANGIOGENESIS INHIBITOR; ANTIBODY; ARGINYLGLYCYLASPARTIC ACID ANTIBODY; AURISTATIN PE; AVE 8062A; COMBRESTATIN A4 PHOSPHATE; COMBRETASTATIN A1 PHOSPHATE; ENDOGLIN ANTIBODY; EXHERIN TM; FAS ANTIBODY; GELONIN; INTERLEUKIN 12 ANTIBODY; MITOFLAXONE; MITOFLAXONE 2 DIETHYLAMINOETHYL ESTER; N ACETYLCOLCHINOL PHOSPHATE; PHOSPHATIDYLSERINE ANTIBODY; PROSTATE SPECIFIC ANTIGEN ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIBODY; RAF PROTEIN; RICIN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TISSUE FACTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE-1 ANTIBODY; VASCULAR TARGETING AGENT; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ABSENCE OF SIDE EFFECTS; ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTICLE; BONE MARROW TOXICITY; BRAIN ISCHEMIA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFECT; DYSPNEA; FATIGUE; GENE THERAPY; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIA; LEUKOPENIA; LIGAND BINDING; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTOPENIA; NAUSEA; NEPHROTOXICITY; PAIN; PRIORITY JOURNAL; QT PROLONGATION; SEDATION; SIDE EFFECT; SLURRED SPEECH; STOMATITIS; TREMOR; TUMOR GROWTH; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; URINE INCONTINENCE; VASCULAR ENDOTHELIUM; VISUAL DISORDER; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; FLAVONOIDS; LIGANDS; NEOPLASMS; TUBULIN; XANTHONES;

EID: 33750539995     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20783     Document Type: Article

References (113)

1. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. 2003. Assessment of pharmacodynamic vascular response in a phase I trial of combrestatin A4 phosphate. J Clin Onc 21:2823-2830.
2. Atassi G, Briet P, Berthelon JJ, et al. 1985. Synthesis and antitumor activity of some 8-substituted 4-oxo-4H-1-benzopyrans. Eur J Med Chem 5:393-402.
3. Baguley BC. 2003. Antivascular therapy of cancer: DMXAA. Lancet Oncol 4:141-148.
4. Baguley BC, Ching LM. 2002. DMXAA: An antivascular agent with multiple host responses. Int J Rad Onc Biol Phys 54:1503-1511.
5. Baguley BC, Cole G, Thomse LL, Li Z. 1993. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthone-4- acetic acid. Cancer Cheother Pharmacol 33:77-81.
6. Bibby MC, Double JA. 1993. Flavone acetic acid-from laboratory to clinic and back. Anticancer Drugs 4:3-17.
7. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. 2002a. ZD6126: A novel small molecule vascular targeting agent. Int J Radiat Oncol Bio Phys 54:1497-1502.
8. Blakey DC, Westwood FR, Walker M, Hughes GD, David PD, Ashton SE, Ryan AJ. 2002b. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983.
9. Brown JM, Le QT. 2002. Tumor hypoxia is important in radiotherapy, but how should we measure it? Int J Rad Onc Biol Phys 54:1299-1301.
10. Burke PA, DeNardo SJ. 2001. Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Onc Hemat 39:155-171.
11. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM. 1999. Thalidomide increases both intra-tumoral tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4- acetic acid. Br J Cancer 80:716-723.
12. Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407:249-257.
13. Carpenito C, Davis PD, Dougherty ST, Dougherty GJ. 2002. Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer. Int J Rad Onc Biol Phys 54:1473-1478.
14. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 25:3666-3670.
15. Chang SS, Heston WD. 2002. The clinical role of prostate-specific membrane antigen (PSMA). Urol Oncol 7:7-12.
16. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. 1999. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated vasculature. Cancer Res 59:3192-3198.
17. Chaplin DJ, Hill SA. 2002. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Rad Onc Biol Phys 54:1491-1496.
18. Chaplin DJ, Pettit GR, Hill SA. 1999. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195.
19. Ching LM, Joseph WR, Crosier RE, Baguley BC. 1994. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54:870-872.
20. Ching LM, Godlsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC. 1999. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethyxanthenone-4-acetic acid (DMXAA in TNF knockout mice. Cancer Res 59:3304-3307.
21. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. 1994. Combining bioreductive drugs (SR4233 or SN23862) with the vasoreactive agents flavone acetic acid or 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 24:373-377.
22. Corbett TH, Bissery MC, Wozniak A, Plowman J, Polic L, Tapazoglou E, Dieckman J, Valeriote F. 1986. Activity of flavone acetic acid (NSC-34512) against solid tumors in mice. Invest New Drugs 4:207-220.
23. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. 1997. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834.
24. Davis PD, Tozer GM, Naylor MA, Thomson P, Lewis G, Hill SA. 2002. Enhancement of vascular targeting by inhibitors of nitric oxide synthase. Int J Radiat Oncol Bio Phys 54:1532-1536.
25. deJonge MJ, van der Gaast A, Planting AS, van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J. 2005. Phase 1 and pharmacokinetic study of the dolastatin 10 analogue TZT-1027 given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 15:3806-3813.
26. DelProposto Z, LoRusso P, Latif Z, Morton P, Wheeler C, Barge A, Evelhoch J. 2002. MRI evaluation of the effect of the vascular-targeting agent ZD6126 on tumor vasculature. Proc Am Soc Clin Oncol 21:110a. Abstract 440.
27. Denekamp J. 1990. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9:267-282.
28. Denekamp J. 1993. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radio 66:181-186.
29. Dorr T, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. 1996. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest New Drugs 14:131-137.
30. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. 2002. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416.
31. El-Zayat AAE, Degen D, Drabek S, Clark GM, Petitt GR, Von Hoff DD. 1993. In vitro evaluation of the antineoplastic actitiy of combretastatin A-, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 4:19-25.
32. Evelhoch JL, LoRusso PM, He Z, DeProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC. 2004. Magnetic reasonance imaging measurements of the response of murine and human tumors to the vascular targeting agent ZD6126. Clin Cancer Res 10:3650-3657.
33. Folkman J. 1971. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
34. Folkman J. 1999. Angiogenesis research: From Laboratory to clinic. Forum Geneva 9:59-62.
35. Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C. 2002. A dose-escalation study of the novel vascular targeting agent, ZD6126 in patients with solid tumors. Proc Am Soc Clin Oncol 21:110a. Abstract 438.
36. Galbraith SM, Rustin GJS, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR. 2002. Effects of 5,6-dimethyl-xanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic reasonance imaging. J Clin Oncol 20:3826-3840.
37. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Jane Taylor N, Stirling JJ, Sena L, Padhani AR, Rustin GJS. 2003. Combrestatin A4 Phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic contrast-enhanced magnetic reasonance imaging. J Clin Oncol 21:2831-2842.
38. Gaya AM, Rustin GJS. 2005. Vascular disrupting agents: A new class of drug in cancer therapy. Clin Oncol 17:277-290.
39. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91.
40. Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D. 2003. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to necrosis factor alpha. Cancer Res 63:3202-3210.
41. Hande KR, Meek K, Lockhart AC, Glad-Anderson S, Berlin J, Eliopoulos H, Roth B, Roberts P, Rothenburg ML. 2003. Pharmacokinetics and safety profile of ABT-751, a novel microubulin inhibitor. Pro Am Clin Onc 22:130. Abstract #520.
42. Hill SA, Tozer GM, Pettit GR, Chaplin D. 2002. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi4503. Anticancer Res 22:1453-1458.
43. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. 2002. Tumor regression by targeted gene deliver to the neovasculature. Science 296:2314-2315.
44. Horsman MR, Ehrnrooth E, Laderkarl M, Overgaard J. 1998. The effect of combretastatin A-4 phosphate in a C3H mous mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Bio Phys 42:895-989.
45. Horsman MR, Murata R, Overgaard J. 1999. Improving conventional cancer therapy by targeting tumour vasculature. Br J of Cancer 80:90. (P247).
46. Hu P, Yan J, Sharifi J, Bai T, Khawli A, Epstein A. 2003. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res 63:5046-5053.
47. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. 1997. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547-550.
48. Huang X, He BJ, Watkins L, Thorpe P. 2004. Antiphosphatidylserine monoclonal antibody 3G4 enhances the anti-tumour effects of docetaxel against human breast carcinoma. Proc Am Assoc Cancer Res 45:1498.
49. Iyer S, Chaplin DJ, Rosenthal DS, Hamid Boulares A, Li LY, Smulson ME. 1998. Induction of apoptosis in proliferating human endothelial cells by tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58:4510-4514.
50. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P. 2003. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Brit J of Cancer 88:1844-1850.
51. Jonker DJ, Avruch L, Stewart DJ, Goel G, Goss G, Reaume MN, Spencer A, Peters WP. 2004. A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression. Proc Am Soc Clin Oncol 23:214. Abstract 3078.
52. Jonker DJ, Stewart DJ, Goel R, Avruch L, Goss G, Maroun J, Cripps C, Wells R, Malik K, Peters WP. 2005. A phase I study of the novel molecularly targeted vascular targeting agent, Exherin™ (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression. Proc Am Soc Clin Oncol 23:201. Abstract 3038.
53. Kanwar JR, Danwar RK, Pandey S, Ching LM, Krissansen GW. 2001. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to eradication of large tumors and multiple tumor foci. Cancer Res 61:1948-1956.
54. Kelland LR, Baguley BC, Zhao L, Ding Q, Kestell P, Ravic M, Jameson MB, McKeage MJ. 2005. Plasma levels of 5-hydrocyindole-3-acetic acid (5HIAA) as a pharmacodynamic marker of blood flow changes induced by the vascular targeting agent (VTA) 5,6, dimethyl xanthenone acetic acid, DMXAA. Proc Am Soc Clin Oncol 23:222. Abstract 3123.
55. Kerr DJ, Kaye SB, Graham J, Cassidy J, Harding M, Setanoians A, McGrath JC, Vezin WR, Cunningham D, Forrest G, et al. 1986. Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res 46:142-146.
56. Kerr DJ, Kaye SB, Cassidy J, Bradley C, Rankin EM, Adams L, Setanoians A, Young T, Forrest G, Soupkop M, et at. 1987. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47:6776-6781.
57. Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K, Tsukagoshi S. 1997. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88:316-327.
58. Lash CJ, LI AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. 1998. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination wit h5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78:439-445.
59. Lejeune P, Hodge TG, Vrignaud P, et al. 2002. In vivo antitumor activity and tumor necrosis induced by AVE8062A, A tumor vasculature targeting agent. AACR Proceedings 43:156. Abstract 781.
60. Liekens S, De Clercq E, Neyts J. 2001. Angiogenesis: Regulators and clinical applications. Biochem Pharmacol 61:253-270.
61. Lienard D, Ewalenko P, Delmotte P, Renard N, Lejeune FJ. 1992. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52-60.
62. Lienard D, Eggermont AM, Schraffordt KH, Kroon BB, Rosenkaimer F, Autier P, Lejeune FJ. 1994. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (INF-gamma) and melphalan for melanoma stage III. Results of a mutil-centre pilot study. Melanoma Res 4 Suppl 1:21-26.
63. Ludford RJ. 1945. Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst 6:89-101.
64. Luo Y, Mohning KM, Nuss ME, et al. 2002. A novel antitubulin agent (ABT-751) selectively reduces tumor perfusion in a subcutaneous rat tumor model as measured by MRI. AACR Proceedings 43:157. Abstract 784.
65. MacPherson GG, North RJ. 1986. Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology. Cancer Immunol Immunother 21:209-216.
66. Mahadevan V, Malik ST, Meager A, Fiers W, Lewis GP, Hart IR. 1990. Role of tumor necrosis factor in flavone acetic acid-induced tumor vascular shutdown. Cancer Res 50:5537-5542.
67. Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE. 2001. Combretastatin A4 prodrug study of effect on the growth and microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7:1052-1060.
68. Manda T, Nishigaki F, Mori J, Shimomura K. 1988. Important role of serotonin in the antitumor effects of recombinant human tumor necrosis factor-alpha in mice. Cancer Res 48:4250-4255.
69. McGown AT, Fox BW. 1990. Differential cytotoxicity of combretastatins A-1 and A-4 in two daunorubicin-resistant P388 cell lines. Cancer Chemother Pharmacol 26:79-81.
70. McKeage M, Fong P, Jeffery M, Ravic MB, Jameson MB. 2005. DART- A phase I safety and dose-finding study of the vascular targeting agent 5,6-dimethylcanthenone-4-acetic acid (DMXXA) in the treatment of refractory tumors. Proc Am Soc Clin Oncol 23:212. Abstract 3081.
71. Milowsky MI, Rosmarin AS, Cobham MV, Navarro MV, Keresztes RS, Kostakoglu L, Smith-Jones P, Vallabhajosula S, Kim SW, Liu H, Goldsmith SJ, Bander NH, Nanus DM. 2002. Anti-PSMA mAB huJ591 specifically targets tumor vascular endothelial cells with advanced solid tumor malignancies. Proc Am Soc Clin Onc 21:8. Abstract #29.
72. 90Y)-labeled anti-prostate specific membrane antigen (PMSA) monoclonal antibody (mAB) J591 in the treatment of patients with advanced prostate cancer (PC). Proc Am Soc Clin Onc Chicago, IL 22:394. Abstract #1583.
73. Murata R, Overgaard J, Horsman MR. 2002. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation and mild hyperthermia. Int J Radiat Oncol Bio Phys 51:1018-1024.
74. Ohsumi K, Hatanaka T, Nakagaw R, Fukuda Y, Morinaga Y, Suga Y, Nihei Y, Ohishi K, Akiyama Y, Tsuji T. 1999. Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Anticancer Drug Des 14:539-548.
75. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, Begent RH. 1996. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 56:3293-3300.
76. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH. 1999. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an activascular agent. Cancer Res 59:3998-4003.
77. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH. 2001. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 61:4716-4722.
78. Pedley RB, El-Emir E, Flynn A, Boxer GM, Dearling J, Raleigh JA, Hill SA, Stuart S, Motha R, Begent RHJ. 2002. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Bio Phys 54:1524-1531.
79. Philpott M, Baguley BC, Ching LM. 1995. Induction of tumour necrosis factor-α by single and repeated doses by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36:143-148.
80. Philpott M, Joseph WR, Crosier KE, Baguley BC, Ching LM. 1997. Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 76:1586-1591.
81. Pruijn FB, van Daalen M, Hoford NH, Wilson WR. 1997. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 39:541-546.
82. Raben D, Bianco C, Daminano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. 2004. Antitumor activity of ZD6126, a novel vascular targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther 3:977-983.
83. Radema SA, Beerepoot LV, Wittevee PO, Gebbink MF, Wheeler C, Voest E. 2002. Clinical evaluation of the novel vascular-targeting agent, ZD6126: Assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 21:110a. Abstract 439.
84. Ran S, Thorpe PE. 2002. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imagining and therapy. Int J Rad Onc Biol Phys 54:1479-1484.
85. Remick SC. 2002. Vascular Targeting: Cinical Experience. Horizons in Cancer Therapeutics: From Bench to Bedside 3:16-23.
86. Rewcastle GW, Atwell GJ, Baguley BC, Boyd M, Thomsen LL, Zhuang L, Denny WA. 1991. Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 34:2864-2870.
87. Rowinsky EK. 2002. Editorial: Targeting the Tumor Vasculature. Horiz Cancer Thera: From Bench to Bedside 3:2-3.
88. Rustin GJS, Galbraith SM, Anderson H, Starford M, Folkes LK, Sena L, Gumbrell L, Price PM. 2003. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822.
89. Schoffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M. 2004. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1 hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 15:671-679.
90. Seon BK, Takahashi N, Haba A, Matsuno F, Haruta Y, She XW, Harada N, Tsai H. 2001. Angiogenesis and metastasis marker of human tumors. Rinsho Byori 10:1005-1013.
91. Sessa C, LoRusso P, Tolcher AW, Braghetti A, Besenval M, Terrot T, DeNaro S, Daglish B, Veyrat-Follet C, Fontaine H, Marsoni S. 2005. A pharmacokinetic and DCE-MRI-dynamic Phase I study of the antivascular combrestatin analogue AVE8062A administered every 3 weeks. Am Ass Cancer Res Proc 46:1371. Abstract #5827.
92. Siemann DW. 2002. Vascular Targeting Agents. Horiz Cancer Ther: From Bench to Bedside 3:4-15.
93. Siemann DW, Rojiani AM. 2002. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Rad Onc Biol Phys 53:164-171.
94. Siemann DW, Mercer E, Lepler S, Rojiani AM. 2002. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6.
95. Siemann DW, Chaplin DJ, Horsman MR. 2004. Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491-2499.
96. Siim BG, Pruijn FB, Shalal-Zwain S, McKeage MJ, Wilson WR. 2003. Marked potentiation of the antitumour activity of chemotherapy drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51:43-52.
97. Skipper HE. 1971. Cancer chemotherapy is many things: HA Clowes Memorial Lecture. Cancer Res 31:1173-1180.
98. Starnes CO. 1994. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol Ther 64:529-564.
99. Stevenson JP, Rosen M, Sun W, Gallagher M, haller DG, Vaughn D, Giantonio B, Zimmer R, Petro WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ. 2003. Phase I trial of the antivascular agent combrestatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imagin evidence for altered tumor flow. J Clin Oncol 21:4428-4438.
100. Thorpe PE, Chaplin DJ, Blakey DC. 2003. The first international conference on vascular targeting: Meeting overview. Cancer Res 63:1144-1147.
101. Tolcher AW, Forero L, Celio P, Hammond LA, Patnaik A, Hill M, Verat-Follet C, Haacke M, Besenval M, Rowinsky EK. 2003. Phase I, pharmacokinetic and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. Pro Am Soc Clin Oncol 22:208. Abstract 834.
102. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ. 1999. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 59:1626-1634.
103. Tsunoda S, Ohizumi I, Matsui J, Koizumi K, Wakai Y, Makimoto H, Tsutsumi Y, Utoguchi N, Taniguchi K, Saito H, Harada N, Ohsugi Y, Mayumi T. 1999. Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue. A novel drug carrier for cancer targeting therapy. Br J Cancer 81:1155-1161.
104. van Hinsbergh VWM, Collen A, Koowijk P. 1999. Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors. Ann Oncol 10:560-563.
105. Varner JA, Cheresh DA. 1996. Tumor angiogenesis and the role of vascular cell integrin ανβ3. Important Adv Oncol 69-87.
106. 121/rGelonin chimeric fusion toxic targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 99:7866-7871.
107. Walsh WH. 1844. The anatomy, physiology, pathology and treatment of cancer. Boston: Ticknor and Co.
108. Wilcox WS. 1966. The last surviving cancer cell. Chemo Cancer Reports 50:541-542.
109. Wilson WR, Baguley BC. 2000. Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int J Radiat Oncol Biol Phys 46:706.
110. Wilson WR, Li AE, Cowan DS, Sum BG. 1998. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42:905-908.
111. Woglum WH. 1923. A critique of tumor resistance. J Cancer Res 7:283-311.
112. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P. 2002. Hypoxia as a target for combined modality treatments. Euro J Cancer 38:240-257.
113. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Shahelijo L, Gordon GB, Kantarijan HM, Giles FJ. 2005. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11:6615-6624.